HIMALAYA THERAPEUTICS - Key Persons

Job Titles:

• CHIEF EXECUTIVE OFFICER

Dr. Zhang brings decades of experience in life sciences to lead Himalaya. He is a venture partner at Yuanming Capital and an angel investor, focused on biomedical investment. He was president and cofounder of Tairan Biopharma and founder/CEO of Novomed Technologies. Dr. Zhang co-invented the first gene chip-based diagnostic for subtyping breast cancers when he was at Arcturus Applied Genomics in San Diego, California. Dr. Zhang also spent a decade at Hoffmann-La Roche in Nutley, New Jersey, where he held many roles, including Senior Scientist and Principal Investigator, and he was involved in the development of Xenical, the world's first oral obesity drug, and the discovery of Dorzagliatin, for type II diabetes. He was a leader overseeing the Roche-Takeda project and a team member of the first interdepartmental bioinformatics project for Roche US, leading and building an animal disease model center and implemented a database system to support Roche globally. Dr. Zhang was at PricewaterhouseCoopers (PwC) in New York as a Senior Business Consultant, where he led and provided business analysis and information system consultation to the pharmaceutical industry in the tri-state area. He received his B.S. in Biology from Nanjing University, did brain research at the Graduate School of the Chinese Academy of Sciences before earning a highly competitive scholarship to study abroad, and he received his Ph.D. in Neuroscience from the UCLA School of Medicine. Dr. Zhang is an author on dozens of peer reviewed publications in top scientific journals

Job Titles:

• CHIEF OPERATING OFFICER
• CO - FOUNDER
• PRESIDENT

Carolyn Short cofounded Himalaya and is its President & COO. Ms. Short is also co-founder of BioAtla®, and was head of global intellectual property and business strategy for the company from inception through its' successful IPO until May of 2021. While at BioAtla, prior to the IPO, she helped the company raise over $100M out of partnerships with Chinese biopharma companies and investors. Ms. Short was head of the intellectual property group of Diversa Corporation (now BASF) from the company's inception through her departure after that company's successful IPO, the largest in biotech history at the time. At Diversa, she was part of the team that raised over $500M for the company. Prior to Diversa, Ms. Short held roles in sales, business development, marketing and product management at Stratagene Cloning Systems (currently Agilent). She has decades of experience in business, intellectual property, and licensing/technology transfer matters in a variety of industries, including healthcare, life science, energy, industrial chemicals, agriculture, foods & flavors, diagnostics, research reagents and cleantech. She holds a degree in Biochemistry & Cell Biology from the University of California, San Diego, and is a registered patent agent with the United States Patent & Trademark Office.

Job Titles:

• Anderson Cancer Center
• Chairman of the Department of Immunology

Dr. James Allison is the Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. Among his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Dr. Allison is one of the world's most renowned scientists. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-Debakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.

Job Titles:

• DIRECTOR

Job Titles:

• Chief Medical Officer of BioAtla Inc

Dr. Sievers serves as Chief Medical Officer of BioAtla Inc. He has over 25 years of clinical and translational biomedical research experience in multiple settings, including biotechnology industry, hospital- and clinic-based clinical practice and academics. During his nine years at Seattle Genetics, he was closely involved with the development and regulatory approval of ADCETRIS (brentuximab vedotin), an ADC. Serving in multiple roles of increasing leadership responsibility, he led the Seattle Genetics clinical team and Takeda (Millennium) development partner to design, initiate and enroll four randomized Phase 3 registration trials for ADCETRIS that each ultimately resulted in new indications approved by the FDA. Dr. Sievers has managed clinical development efforts from Phase 1 to Phase 3 clinical trials, from strategy planning to study execution and BLA/NDA submissions. Prior to his career at Seattle Genetics, Dr. Sievers was Medical Director at ZymoGenetics where he designed and supervised clinical trials of recombinant human interleukin 21 and TACI-Fc5 for patients with cancer and evaluated new oncology opportunities. Before then, he was with the Fred Hutchinson Cancer Research Center for 12 years where he attained the position of Assistant Member and was Assistant Professor of Pediatrics at the University of Washington. During this time, he served as the lead investigator of Phase 1 and pivotal trials that resulted in the approval of an antibody drug conjugate MYLOTARG© indicated for patients with acute myeloid leukemia. Dr. Sievers' most recent position was Chief Medical Officer at Trillium Therapeutics where he developed clinical trial strategies and oversaw all clinical development employing a decoy receptor to block the CD47 "do not eat" signal overexpressed by cancer cells. Dr. Sievers received both his medical degree and his B.A. degree from Brown University.

Job Titles:

• CHIEF MEDICAL OFFICER

In addition to his work as CMO of Himalaya, Dr. Li is Founder, DeltaMed, a leading Chinese niche CRO for pharmacovigilance, medical monitoring, medical writing, phase I study and regulatory & clinical development strategy. From 2013 to 2018, Dr. Li was founder and CEO of Tigermed-IntelliPV and former CMO of Tigermed, where he established the pharmacovigilance, medical monitoring and medical information department. He also led Tigermed's medical and scientific affairs department. From 1997-2013, he held several medical management roles in leading global pharma companies, including Quintiles, Abbott Laboratories, Sanofi Pasteur, BMS and Amylin. He was involved 9 NDA submissions as global safety lead. Dr. Li is a committee member of "Executive Management and Translational Medicine", and an Industrial Distinguished Instructor of Tsinghua Medical School. He instructs classes in "Clinical Trial Design" and "Good Practices for Clinical Trials". Dr. Li is also an Adjunct Professor and Counselor of "Clinical Research Center" at the medical school of Shanghai Jiaotong University. He is a professor and class chairman at YeeHong Business School. He is an advisor committee member of the Drug Information Association in China, an International Council for Harmonisation (ICH) expert in China, and China CDE advisor. In addition, he is advisor or partner for several venture capitals. Dr. Li received his MD from Tongji Medical University, Peking Union Medical College. He completed his postdoctoral fellowship in University of North Carolina studied under the Nobel Laureate, Professor Oliver Smithies.

Job Titles:

• CHAIRMAN
• CO - FOUNDER

Dr. Short serves as Chairman and is a cofounder of Himalaya Therapeutics. He is also currently Chairman, CEO, and cofounder of BioAtla® (Nasdaq: BCAB), as well as co-inventor of the BioAtla's patented Conditionally Active Biologics (CAB) / Protein-associated Chemical Switch (PaCS) platform. BioAtla's successful IPO in December 2020 raised over $217 million, and became the second company Dr. Short successfully advanced from founding to IPO. Previously, Dr. Short cofounded Diversa Corporation (now BASF), a pioneering developer of enzymes, antibodies and biologically active compounds, and served in multiple roles including CEO, President and CTO from 1994 to 2005. He led Diversa's public offering, raising over $200 million, which was the largest biotechnology IPO at that time. Prior to Diversa, he was President of Stratacyte, an antibody engineering company and a subsidiary of Stratagene (now Agilent), which together with Scripps Clinic was the first to generate and screen human combinatorial antibody libraries in E. coli. During this time he also served as VP of R&D and Operations for Stratagene Cloning Systems. Dr. Short received his B.A in Chemistry with Honors from Taylor University. At Case Western Reserve University he received his Ph.D. in Biochemistry with additional studies in Macromolecular Science. He is the author of more than 100 peer-reviewed publications and is the inventor of over 500 issued patents. In 2006, Dr. Short was shortlisted by the editors of Nature Biotechnology as one of the people who made the most significant contribution to biotech in the past decade. He is the recipient of numerous other awards, including Ernst & Young's Entrepreneur of the Year Award, the American Chemical Society's Henry F. Whalen, Jr. Award for Business Development, Adaptive Business Leaders' Innovations in HealthCare Gold Award, two of Connect's first place Most Innovative Product Awards and in 2010 received an international Best-of-the-Best award from the Young Presidents Organization (YPO). Dr. Short's board experience includes over 25 years as a director of in public companies serving on audit, compensation and governance committees and is a certified director from the UCLA Anderson School of Business. He is a member of YPO/WPO and a cofounder of Capia IP and founder of the E.O. Wilson Biodiversity Foundation. Dr. Short serves as an advisor to leading educational, commercial, scientific and charitable organizations.

Job Titles:

• DIRECTOR
• Professor of Neurology

Dr. Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and was Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on what provokes relapses and remissions in Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO), and the quest for antigen specific therapy. He is developing a small molecule therapeutic currently in clinical trials for Huntington's Disease. He was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohn's Disease. Dr. Steinman graduated from Dartmouth College, Magna Cum Laude in Physics. His MD is from Harvard Medical School. He was a post-doctoral fellow in Chemical Immunology at the Weizmann Institute of Science. After a neurology residency at Stanford University he joined the faculty in 1980. He has received numerous honors, including the John M. Dystel Prize in 2004, the Javits Neuroscience Investigator Award from the NINDS twice, and the Charcot Prize in MS research. Dr. Steinman is a member of the National Academy of Sciences and the National Academy of Medicine. Dr. Steinman holds 41 patents. He cofounded several biotech companies including Neurocrine Biosciences, Bayhill Therapeutics (now Tolerion), Nuon Therapeutics, Transparency Life Sciences and Atreca. He was a Director of Centocor from 1988 until its sale to Johnson and Johnson. He currently serves as a Director of BioAtla.

Job Titles:

• CHIEF FINANCIAL OFFICER
• CORPORATE DEVELOPMENT OFFICER

Before joining Himalaya, Mr. Desjardins was a partner at ASGARD, a merchant bank, overseeing its advisory practice. Previously, he was a Director in Stifel's Healthcare Investment Banking Group focusing on the biotech sector, and an Associate in Cowen's Healthcare and TMT Investment Banking Groups. During his time at Cowen and Stifel, he worked on transactions in excess of $10 billion in value, including helping raise $1.4 billion in 17 IPOs. Prior to this, he worked in the Distressed Investing Group at KP Capital Partners focusing on restructuring and turnarounds, and spent ten years working in finance and operational capacities at companies in China and Asia Pacific, including PriceWaterhouse, Beijing RELTEC and MSL Express. Mr. Desjardins holds an MBA in Finance from the Yale School of Management, a BA in History from Yale College and a BS in Accounting, summa cum laude, from The State University of New York at Plattsburgh. He studied Mandarin Chinese at the National Taiwan Normal University and speaks and reads it fluently.

Job Titles:

• DIRECTOR
• Chief Financial Officer of BioAtla Inc

Mr. Waldron currently serves as Chief Financial Officer of BioAtla Inc since 2014. BioAtla achieved a successful IPO in December 2020. Mr. Waldron has extensive experience in the financing and executive operations of biotechnology companies. He has served as the Chief Financial Officer of three publicly traded companies, successfully raising capital for all three and executing the merger of one of them. Prior to his work in the industry, Mr. Waldron served as a senior health care banker, executing strategically significant transactions and pioneering financial strategies for clients that included Genzyme and Genentech, and initiated the sector practice at Cowen & Company, a leading healthcare investment bank. Mr. Waldron graduated with honors from Harvard Business School, and magna cum laude from Princeton University.

Job Titles:

• DIRECTOR
• Director of Himalaya

Mr. Smith is a Director of Himalaya with over 30 years of biotechnology and pharmaceutical industry experience. He is currently President and Director of BioAtla®, since 2018. BioAtla achieved a successful IPO in December 2020. In his ten years at Celgene from 2008-2018 his leadership role expanded from Vice President of Global Marketing for Inflammation & Immunology, to Global Head of that division, to President of the Inflammation & Immunology Franchise to his appointment in 2017 as Celgene's President and Chief Operating Officer. With a particular emphasis and interest in immunology, Mr. Smith drove the growth of Celgene's Inflammation and Immunology division from 13 to more than 1,300 people worldwide and oversaw the clinical development, global registration and commercial success of the blockbuster drug Otezla. Mr. Smith's prior experience at Pharmacia (acquired by Pfizer) and at Biovail included global responsibility for sales and marketing, creating and executing commercial and business development strategies and contributing to regulatory and clinical development strategies. Mr. Smith also serves on the board of directors of Apexigen, Triumvira Immunologics, Refuge Bio and is an investment advisor to 3E Bio. Mr. Smith received both his BSc degree in Chemistry and Biology and his HBSc degree in Pharmacology and Toxicology from the University of Western Ontario and his Masters of International Business Management from the American Graduate School of International Management (Thunderbird).

Job Titles:

• CHIEF of TRANSLATIONAL MEDICINE

Dr. Boyle has over 25 years of pharmaceutical and biotechnology industry experience including leadership roles in private start-up and multinational companies. Dr. Boyle was most recently Chief of Translational Medicine and a Research Fellow at BioAtla Inc. He was President of VivaMab, a drug development division of BioAtla involved in the discovery and development of therapeutic antibodies. Prior to that he was President and Chief Science Officer at Anaptysbio, and former Director of Research at Amgen, Inc. where he led the discovery and early preclinical development of Denosumab, a RANKL-targeted therapeutic antibody. Dr. Boyle holds a Doctoral degree in Experimental Pathology from the UCLA School of Medicine, and was a Howard Hughes Medical Institute Postdoctoral Fellow of the Life Sciences Research Foundation at the Salk Institute in La Jolla. He also currently serves on the Board of Directors for Alethia Biotherapeutics, a biotechnology company focused on new treatments for ovarian cancer.

Job Titles:

• VICE PRESIDENT of MEDICAL
• VICE PRESIDENT of MEDICAL and CLINICAL OPERATIONS

Dr. Li has over 15 years of experience through global translational research, clinical development, and medical affairs. Dr. Li used to be a doctor and PhD supervisor in Tier 3 Hospital in Shanghai, China, leading the grant of "National Natural Science Foundation". Then she worked in Top 10 Global Pharms AstraZeneca, Novartis, Abbott and Chinese Pharma Hengrui, played critical roles in physician, Medical Manager, TA head and National Medical Director in broad therapeutic areas of Oncology, Rheumatology & Immunology, Gastroenterology& Hepatology, Hematology, Nephrology, Cardiovascular disease, Diabetes, etc. She successfully built medical and clinical operation team, managed over 100 clinical trials, owns a stellar track-record in shaping innovative portfolio development and products launching strategy. Dr. Li received her Ph.D. degree of Medicine from Erasmus Medical Center in the Netherlands (Top1 Medical Center in Europe 2009), where she discovered the role of IL-6/IL-17 signaling and JAK/STAT/SOCS pathway in autoimmune disease and GI oncology. She received her M.D. title from Wuhan University Zhongnan Hospital, and her EMBA degree from Shanghai Jiao-Tong University in China. Dr. Li has 10 book publications, 57 scientific manuscript & poster publications, and 10+ Chinese guidelines contribution. She served editor role in 10+ scientific journals. In China professional societies and advisory committees, she worked as Editor-in-Chief on public books of "Guideline on Post marketing Studie" and "RWD and RWE" where earned great honor and impact.